Breakthrough pain (BTP) currently represents a challenge for health professionals dedicated to the treatment of pain. In this descriptive 1-year follow-up study on three patients with BTP from vertebral crush, in the context of multiple myeloma, the authors have observed the great either efficacy or tolerability profile of fentanyl pectin nasal spray. The most relevant findings in this study were better adherence to treatment compared to previously opioids and also great personal satisfaction. Because of common pathophysiological mechanism for noncancerous pain of bone origin, these good results could open the door to investigation of the use of this drug in this patient's group.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.5055/jom.2016.0332 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!